Zacks: Analysts Expect Teladoc Health Inc (TDOC) to Post -$0.35 EPS


Analysts expect that Teladoc Health Inc (NYSE:TDOC) will post earnings per share (EPS) of ($0.35) for the current quarter, according to Zacks. Ten analysts have provided estimates for Teladoc Health’s earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.40). Teladoc Health reported earnings of ($0.50) per share during the same quarter last year, which suggests a positive year over year growth rate of 30%. The business is expected to report its next quarterly earnings report on Tuesday, February 26th.


According to Zacks, analysts expect that Teladoc Health will report full-year earnings of ($1.48) per share for the current financial year, with EPS estimates ranging from ($1.52) to ($1.33). For the next financial year, analysts expect that the company will post earnings of ($1.07) per share, with EPS estimates ranging from ($1.40) to ($0.60). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for Teladoc Health.

Get Teladoc Health alerts:


TDOC has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded Teladoc Health from a “hold” rating to a “buy” rating and set a $54.00 target price for the company in a research report on Saturday, January 5th. Jefferies Financial Group set a $95.00 price objective on Teladoc Health and gave the company a “buy” rating in a research report on Friday, November 2nd. Chardan Capital upped their price objective on Teladoc Health from $98.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, November 2nd. Craig Hallum upped their price objective on Teladoc Health from $70.00 to $80.00 and gave the company a “buy” rating in a research report on Monday, October 15th. Finally, Berenberg Bank began coverage on Teladoc Health in a research report on Thursday, January 31st. They issued a “buy” rating and a $80.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $83.84.


Shares of NYSE:TDOC traded up $0.34 during midday trading on Friday, reaching $62.59. The company’s stock had a trading volume of 702,970 shares, compared to its average volume of 1,124,770. Teladoc Health has a fifty-two week low of $31.80 and a fifty-two week high of $89.05. The firm has a market cap of $4.39 billion, a PE ratio of -37.93 and a beta of 1.47. The company has a debt-to-equity ratio of 0.40, a quick ratio of 8.99 and a current ratio of 8.99.

In related news, insider Adam C. Vandervoort sold 5,550 shares of the company’s stock in a transaction on Monday, December 10th. The shares were sold at an average price of $54.19, for a total value of $300,754.50. Following the sale, the insider now directly owns 2,934 shares of the company’s stock, valued at $158,993.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jason N. Gorevic sold 30,000 shares of the company’s stock in a transaction on Friday, January 18th. The shares were sold at an average price of $63.04, for a total transaction of $1,891,200.00. Following the completion of the sale, the chief executive officer now directly owns 633,719 shares in the company, valued at $39,949,645.76. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 130,194 shares of company stock valued at $7,383,442. Insiders own 3.95% of the company’s stock.


Institutional investors and hedge funds have recently bought and sold shares of the stock. Enlightenment Research LLC acquired a new stake in Teladoc Health in the 4th quarter valued at about $25,000. Nikko Asset Management Americas Inc. purchased a new stake in Teladoc Health during the fourth quarter valued at about $25,000. Ffcm LLC purchased a new stake in Teladoc Health during the fourth quarter valued at about $32,000. Parkside Financial Bank & Trust lifted its position in shares of Teladoc Health by 1,455.0% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,244 shares of the health services provider’s stock worth $62,000 after purchasing an additional 1,164 shares in the last quarter. Finally, Penserra Capital Management LLC purchased a new stake in shares of Teladoc Health in the fourth quarter worth approximately $83,000.


About Teladoc Health

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Further Reading: Return on Equity (ROE)

Get a free copy of the Zacks research report on Teladoc Health (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teladoc Health (NYSE:TDOC)